Rigel Pharmaceuticals RIGL Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $597K-1.2% | $601K-0.5% | $603K-1.3% | $607K-1.0% | $604K+51.0% | ||
| $3.46M+4.0% | $2.75M+31.7% | $3.36M+27.2% | $3.28M+29.6% | $3.32M-35.3% | ||
| $2.57M— | —— | —— | —— | $0— | ||
| -$1.82M-2,574% | $5.84M-47.1% | $6.02M+260% | -$1.64M-218% | -$68K+97.8% | ||
| $581K+141% | —— | —— | $8.37M+281% | -$1.41M-161% | ||
| -$2.71M-540% | $3.35M+803% | —— | $3.34M+206% | $615K-71.2% | ||
| -$5.91M-43.5% | $1.85M-16.5% | —— | —— | -$4.12M-20.0% | ||
| $3.79M-71.2% | $3.39M— | $1.87M+34.1% | —— | $13.15M+409% | ||
| -$145K-114% | —— | —— | —— | $1.04M+716% | ||
| $2.73M+405% | $21.98M+51.6% | $24.03M+10.8% | $30.54M+10,012% | -$893K+82.2% | ||
| —— | $1.25M0.0% | $1.25M0.0% | $1.25M0.0% | $1.25M0.0% | ||
| $23.92M+10.5% | $38.92M+120% | $53.89M+2,334% | $39.03M+417% | $21.65M+178% | ||
| $15.95M+43.6% | $13.55M+101% | $20.73M+246% | $15.75M-15.8% | $11.1M+34.5% | ||
| -$7.98M+24.4% | -$25.36M— | -$33.18M-973% | -$23.28M-313% | -$10.55M-3,471% | ||
| $3.74M— | —— | —— | —— | $0— | ||
| $7.5M— | —— | —— | —— | $0— | ||
| $321K-33.7% | $2.93M+99.9% | $4.27M+2,603% | $418K+65.9% | $484K+444% | ||
| -$10.92M-2,356% | —— | $4.27M+143% | $418K+156% | $484K+119% | ||
| -$16.17M-47.5% | -$7.95M-257% | -$4.87M-131% | —— | -$10.96M-52.0% | ||
| $1.32M-20.1% | $1.56M-10.5% | $1.68M-8.6% | $1.68M-5.3% | $1.65M-1.8% | ||
| —— | $265.75K+221% | $265.75K+221% | $265.75K+221% | $265.75K+221% | ||
| $218K-62.1% | $708K+47.5% | $695K— | —— | $575K-6.4% | ||
| -$5.91M-43.5% | $1.85M-16.5% | —— | —— | -$4.12M-20.0% | ||
| -$145K-114% | —— | —— | —— | $1.04M+716% | ||
| -$1.79M+39.3% | —— | —— | —— | -$2.95M-3,025% | ||
| $3.79M-71.2% | $3.39M— | $1.87M+34.1% | —— | $13.15M+409% | ||
| $135K+113% | —— | —— | —— | -$1.06M-811% | ||
| $170K-10.5% | $243K-12.0% | $467K+577% | $250K+57.2% | $190K-7.3% | ||
| $364K-75.7% | —— | $518K-85.8% | $1.57M-37.4% | $1.5M+314% | ||
| $23.92M+10.5% | $38.92M+120% | $53.89M+2,334% | $39.03M+417% | $21.65M+178% | ||
| $15.95M+43.6% | $13.55M+101% | $20.73M+246% | $15.75M-15.8% | $11.1M+34.5% | ||
| $321K-33.7% | $2.93M+99.9% | $4.27M+2,603% | $418K+65.9% | $484K+444% | ||
| $7.5M— | —— | —— | —— | $0— | ||
| -$145K-114% | —— | —— | —— | $1.04M+716% | ||
| $5M0.0% | —— | —— | —— | $5M— | ||
| $0-100% | —— | —— | —— | $1.22M— | ||
| —— | $265.75K+221% | $265.75K+221% | $265.75K+221% | $265.75K+221% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Rigel Pharmaceuticals generate?
- Rigel Pharmaceuticals (RIGL) generated $79.3M in operating cash flow over the trailing twelve months.
- Where does Rigel Pharmaceuticals's cash flow data come from?
- Every line is extracted from Rigel Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
